vation of the immune system, with elevations in serum pro-inflammatory cytokines and chemokines, such as interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-α. 3-5 The major source of these cytokines and chemokines has remained a mystery. A previous report analyzed the activation status of peripheral blood mononuclear cells (PBMNCs) by flow cytometry, DNA microarray and quantitative reverse transcription polymerase chain reaction (RT-PCR), finding evidence that the innate immune system appeared to play a role in the pathogenesis and pathophysiology of KD, but it also found that PBMNCs had a low expression of pro-inflammatory cytokine genes. 6 It has therefore been K awasaki disease (KD) is an acute febrile disorder characterized by systemic vasculitis and a high predilection for infants and young children. Although ~5 decades have passed since the disease was first described, 1 its etiology still remains unknown. Approximately 25% of untreated KD patients suffer from coronary artery abnormalities, but the frequency of coronary artery sequelae decreases to 2.8% if treatment with high-dose intravenous immunoglobulin (IVIG) is used. 2 However, ~10-20% of KD patients have persistent fever after this treatment and a high risk for coronary artery sequelae.KD in the acute phase is characterized by marked acti- Background: Approximately 10-20% of Kawasaki disease (KD) patients are resistant to intravenous immunoglobulin (IVIG) treatment. Further, these patients are at a particularly high risk of having coronary artery abnormalities. The mechanisms of IVIG resistance in KD have been analyzed using patient leukocytes, but not patient vascular endothelial cells (ECs). The present study clarifies the mechanisms of IVIG resistance in KD using an induced pluripotent stem cell (iPSC) disease model.
Methods and Results:Dermal fibroblasts or peripheral blood mononuclear cells from 2 IVIG-resistant and 2 IVIG-responsive KD patients were reprogrammed by the episomal vector-mediated transduction of 6 reprogramming factors. KD patient-derived iPSCs were differentiated into ECs (iPSC-ECs). The gene expression profiles of iPSC-ECs generated from IVIG-resistant and IVIG-responsive KD patients were compared by RNA-sequencing analyses. We found that the expression of CXCL12 was significantly upregulated in iPSC-ECs from IVIG-resistant KD patients. Additionally, Gene Set Enrichment Analysis (GSEA) revealed that gene sets involved in interleukin (IL)-6 signaling were also upregulated.
Conclusions:The first iPSC-based model for KD is reported here. Our mechanistic analyses suggest that CXCL12, which plays a role in leukocyte transmigration, is a key molecule candidate for IVIG resistance and KD severity. They also indicate that an upregulation of IL-6-related genes may be involved in this pathogenesis.